Bafetinib (INNO-406)Bcr-Abl/Lyn tyrosine kinase inhibitor CAS# 887650-05-7 |
2D Structure
- CEP-32496
Catalog No.:BCC1079
CAS No.:1188910-76-0
- Sorafenib
Catalog No.:BCN2174
CAS No.:284461-73-0
- Vemurafenib (PLX4032, RG7204)
Catalog No.:BCC1269
CAS No.:918504-65-1
- BRAF inhibitor
Catalog No.:BCC1436
CAS No.:918505-61-0
- PLX-4720
Catalog No.:BCC1280
CAS No.:918505-84-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 887650-05-7 | SDF | Download SDF |
PubChem ID | 24853523 | Appearance | Powder |
Formula | C30H31F3N8O | M.Wt | 576.62 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 50 mg/mL (86.71 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | 4-[[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl]-N-[4-methyl-3-[(5-pyrimidin-5-ylpyrimidin-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide | ||
SMILES | CC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C=C2)CN3CCC(C3)N(C)C)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CN=C5 | ||
Standard InChIKey | ZOPBZHLJXQAQON-VWLOTQADSA-N | ||
Standard InChI | InChI=1S/C30H31F3N8O/c1-19-4-7-24(11-27(19)39-29-36-14-23(15-37-29)22-12-34-18-35-13-22)38-28(42)20-5-6-21(26(10-20)30(31,32)33)16-41-9-8-25(17-41)40(2)3/h4-7,10-15,18,25H,8-9,16-17H2,1-3H3,(H,38,42)(H,36,37,39)/t25-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Bafetinib (INNO-406) is an orally bioavailable, dual inhibitor of Bcr-Abl and Lyn-kinase with IC50 value of 5.8 nM/19 nM, respectively. | |||||
Targets | Abl | Lyn | ||||
IC50 | 5.8 nM | 19 nM |
Bafetinib (INNO-406) Dilution Calculator
Bafetinib (INNO-406) Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.7342 mL | 8.6712 mL | 17.3424 mL | 34.6849 mL | 43.3561 mL |
5 mM | 0.3468 mL | 1.7342 mL | 3.4685 mL | 6.937 mL | 8.6712 mL |
10 mM | 0.1734 mL | 0.8671 mL | 1.7342 mL | 3.4685 mL | 4.3356 mL |
50 mM | 0.0347 mL | 0.1734 mL | 0.3468 mL | 0.6937 mL | 0.8671 mL |
100 mM | 0.0173 mL | 0.0867 mL | 0.1734 mL | 0.3468 mL | 0.4336 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Bafetinib is a potent and selective dual inhibitor of Bcr-Abl/Lyn tyrosine kinase with IC50 values of 5.8nM and 19nM, respectively [1].
Bafetinib is a specific dual Abl-Lyn inhibitor. For 79 other tyrosine kinases, 0.1μM bafetinib can inhibit 4 of these enzymes including Abl, Abl-related gene, Fyn and Lyn. Bafetinib can block the autophosphorylation of Bcr-Abl. In K562 and 293T cells transfected with wt Bcr-Abl, bafetinib shows inhibition with IC50 values of 11nM and 22nM, respectively. In the in vitro kinase assays, bafetinib shows inhibition of a variety of Abl kinase mutants such as M244V, G250E, Y253F and F317L. It has no effect on T315I in vitro. Bafetinib also suppresses the growth of Bcr-Abl–positive leukemic cell lines including K562, KU812 and BaF3/wt. The BaF3/E255K cells are also sensitive towards bafetinib. Moreover, bafetinib is highly potent to inhibit tumor growth in murine tumor models [1].
References:
[1] Kimura S, Naito H, Segawa H, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood, 2005, 106(12): 3948-3954.
- (-)-Holostyligone
Catalog No.:BCN2863
CAS No.:887501-28-2
- Fmoc-Arg(Mts)-OH
Catalog No.:BCC3075
CAS No.:88743-97-9
- INCB 3284 dimesylate
Catalog No.:BCC1646
CAS No.:887401-93-6
- 3,9-Dihydroeucomin
Catalog No.:BCN6832
CAS No.:887375-68-0
- K-115
Catalog No.:BCC5500
CAS No.:887375-67-9
- Hebeirubescensin H
Catalog No.:BCN7155
CAS No.:887333-30-4
- Epiglobulol
Catalog No.:BCN7121
CAS No.:88728-58-9
- Adynerigenin beta-neritrioside
Catalog No.:BCN4556
CAS No.:88721-09-9
- 1alpha-Hydroxytorilin
Catalog No.:BCN6648
CAS No.:887147-75-3
- Borneol 7-O-[beta-D-apiofuranosyl-(1->6)]-beta-D-glucopyranoside
Catalog No.:BCN7814
CAS No.:88700-35-0
- Neobritannilactone B
Catalog No.:BCN3510
CAS No.:886990-00-7
- Piperlotine C
Catalog No.:BCN6485
CAS No.:886989-88-4
- Gaudichaudic acid
Catalog No.:BCN3071
CAS No.:887923-46-8
- Isogambogenic acid
Catalog No.:BCN3076
CAS No.:887923-47-9
- Gambogoic acid B
Catalog No.:BCN7936
CAS No.:887923-50-4
- Galanin (porcine)
Catalog No.:BCC5960
CAS No.:88813-36-9
- Ganetespib (STA-9090)
Catalog No.:BCC2336
CAS No.:888216-25-9
- 11,12-De(methylenedioxy)danuphylline
Catalog No.:BCN4436
CAS No.:888482-17-5
- Sprengerinin C
Catalog No.:BCN6657
CAS No.:88861-91-0
- Adrenorphin, Free Acid
Catalog No.:BCC1011
CAS No.:88866-92-6
- Sprengerinin A
Catalog No.:BCN6658
CAS No.:88866-99-3
- Fosinopril sodium
Catalog No.:BCC2141
CAS No.:88889-14-9
- Inulanolide A
Catalog No.:BCN3705
CAS No.:888941-86-4
- Atrial natriuretic factor (1-28) (rat)
Catalog No.:BCC5843
CAS No.:88898-17-3
KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).[Pubmed:20685234]
Exp Hematol. 2010 Sep;38(9):782-91.
OBJECTIVE: Advanced systemic mastocytosis (SM) is characterized by uncontrolled growth of neoplastic mast cells (MC) and drug resistance. The tyrosine kinase receptor KIT is often mutated and activated and thus contributes to malignant growth of MC. Therefore, KIT-targeting drugs are currently tested for their ability to block growth of malignant MC. MATERIALS AND METHODS: We determined the effects of the multikinase inhibitor INNO-406 (bafetinib) on primary neoplastic MC, the canine mastocytoma cell line C2, the human MC leukemia cell line HMC-1.1 bearing the KIT mutant V560G, and HMC-1.2 cells harboring KIT V560G and KIT D816V. RESULTS: INNO-406 was found to inhibit proliferation in HMC-1.1 cells (IC(50): 30-40 nM), but not in HMC-1.2 cells or primary neoplastic cells in patients with KIT D816V-positive SM. In canines, growth-inhibitory effects of INNO-406 were seen in C2 cells (IC(50): 50-100 nM) exhibiting a KIT exon 11 internal tandem-duplication and in primary neoplastic MC harboring wild-type exon 11, whereas no effects were seen in MC exhibiting a polymorphism at amino acid 581 in exon 11. INNO-406 was found to block KIT phosphorylation and expression in HMC-1.1 cells and C2 cells, but not in HMC-1.2 cells, whereas Lyn-phosphorylation was blocked by INNO-406 in all types of MC. CONCLUSIONS: In neoplastic MC, the major target of INNO-406 appears to be KIT. Drug responses may depend on the presence and type of KIT mutation. In human MC, the KIT D816V mutant introduces resistance, and in canine mastocytomas, an exon 11 polymorphism may be indicative of resistance against INNO-406.
Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters.[Pubmed:27157787]
Sci Rep. 2016 May 9;6:25694.
ATP-Binding Cassette transporters are involved in the efflux of xenobiotic compounds and are responsible for decreasing drug accumulation in multidrug resistant (MDR) cells. Discovered by structure-based virtual screening algorithms, bafetinib, a Bcr-Abl/Lyn tyrosine kinase inhibitor, was found to have inhibitory effects on both ABCB1- and ABCG2-mediated MDR in this in-vitro investigation. Bafetinib significantly sensitized ABCB1 and ABCG2 overexpressing MDR cells to their anticancer substrates and increased the intracellular accumulation of anticancer drugs, particularly doxorubicin and [(3)H]-paclitaxel in ABCB1 overexpressing cells; mitoxantrone and [(3)H]-mitoxantrone in ABCG2 overexpressing cells, respectively. Bafetinib stimulated ABCB1 ATPase activities while inhibited ABCG2 ATPase activities. There were no significant changes in the expression level or the subcellular distribution of ABCB1 and ABCG2 in the cells exposed to 3 muM of bafetinib. Overall, our study indicated that bafetinib reversed ABCB1- and ABCG2-mediated MDR by blocking the drug efflux function of these transporters. These findings might be useful in developing combination therapy for MDR cancer treatment.